VIP acts through exactly two receptors, VPAC1 and VPAC2, class B G protein-coupled receptors that both bind the peptide at roughly 1 to 10 nM and both couple mainly to Gs, adenylyl cyclase, and cAMP. That mechanism rests on structural and cell-physiology evidence, including cryo-EM structures of receptor-Gs complexes, rather than on clinical outcome data. Translating it into a durable systemic therapy has not succeeded, largely because the native peptide is cleared with a half-life of only about one to two minutes.
VIP exerts nearly all of its recognized biological effects through two class B G protein-coupled receptors, VPAC1 and VPAC2, which bind the peptide at roughly 1 to 10 nM and signal predominantly through Gs, adenylyl cyclase, and cAMP.
Class B receptors are built on a different plan from the class A receptors that bind small biogenic amines, and that difference decides what kind of drug can ever hit them. VPAC1 and VPAC2 carry a large extracellular N-terminal module of roughly 120 to 140 residues, locked by three disulfide bridges, that grips the C-terminal half of the peptide before anything else happens. The orthosteric site is therefore a long peptide-shaped groove rather than a small hydrophobic pocket, which is the structural reason decades of medicinal chemistry have produced very few drug-like small molecules for this family.
VPAC1 and VPAC2 follow the class B two-domain mechanism, in which a 120 to 140 residue extracellular domain captures the C-terminal half of VIP and only then allows the peptide's N-terminus to insert into the transmembrane bundle and kink TM6 outward to open the G protein cavity.
The cAMP arm is the best-characterized output of both receptors, and it is also the most sensitive one. Half-maximal cAMP accumulation occurs at VIP concentrations of roughly 0.1 to 5 nM, about a log order below what calcium or MAP kinase responses require in the same cells, so an experiment run at high peptide concentrations reads a mixture of arms rather than the canonical one.
VIP-driven cAMP accumulation at VPAC1 and VPAC2 begins within 15 to 30 seconds and peaks by 2 to 10 minutes, with half-maximal responses at peptide concentrations of about 0.1 to 5 nM.
Describing these as purely Gs-coupled receptors is a simplification that fails as soon as specific tissues are examined. Which arm actually fires is a property of the cell rather than the receptor: the local G protein repertoire, the receptor reserve, the phosphodiesterase and GRK complement, and whether the stimulus is a brief pulse or sustained exposure. That context dependence is why one peptide reads as a relaxant in one tissue, a secretagogue in another, and an immunosuppressant in a third.
Beyond Gs, VPAC receptors recruit Gq and phospholipase C at roughly 10 to 100 nM peptide, show Gi coupling in some smooth muscle and neuronal tissue, and signal through beta-arrestin to drive delayed ERK1/2 activation from the endosome.
Because both subtypes generate the same core second messenger, the organ decides the effect rather than the receptor. VPAC1 is the broader and more epithelial of the two, while VPAC2 sits on excitable and secretory tissue. The immune distribution is the part most often misread as fixed: resting T cells carry mostly VPAC1, but T cell receptor engagement downregulates VPAC1 and induces VPAC2, so an activated effector T cell reads the same peptide through a different receptor than it did before activation.
| Compartment | VPAC1 | VPAC2 |
|---|---|---|
| Epithelial and visceral organs | Lung parenchyma, airway epithelium, liver, kidney, intestinal and colonic mucosa, prostate | Pancreatic islets, cardiac tissue, skeletal muscle |
| Smooth muscle | Minor contribution | Vascular, airway, gastric, and intestinal smooth muscle |
| Immune cells | Resting T lymphocytes, monocytes, thymus, spleen | Induced on activated T cells |
| Nervous system | Limited | Suprachiasmatic nucleus, specific brain nuclei |
| Tumors | High density on breast, prostate, colon, pancreatic, and lung adenocarcinomas | Not a general tumor marker |
VPAC1 dominates epithelial, hepatic, renal, and resting immune tissue while VPAC2 dominates vascular and airway smooth muscle, pancreatic islets, and the suprachiasmatic nucleus, so tissue distribution rather than second-messenger identity determines what VIP does in a given organ.
The two receptors are much harder to separate in the laboratory than their distinct names suggest. Neither VIP nor PACAP-38 is subtype-selective, both binding within a few-fold of each other at 1 to 10 nM, so every clean subtype question depends on engineered analogues whose selectivity margins run in the tens to hundreds of fold rather than absolute specificity.
VPAC1 and VPAC2 are not redundant despite sharing both natural ligands, since VPAC2-null mice show flattened circadian rhythms and altered glucose handling while VPAC1-null mice show pulmonary and immune phenotypes, and neither loss is rescued by the remaining subtype.
PAC1 is the third receptor in the family and the one that breaks the symmetry. It binds PACAP-38 and PACAP-27 with roughly 100 to 1000 fold higher affinity than VIP, which removes it from most VIP physiology at physiological peptide concentrations and leaves it as a confound to rule out rather than a partner receptor. Its variability comes from alternative splicing rather than from ligand promiscuity.
| Property | PAC1 | VPAC1 and VPAC2 |
|---|---|---|
| PACAP versus VIP affinity | 100 to 1000 fold preference for PACAP | Within a few-fold, roughly 1 to 10 nM for both |
| Source of signaling diversity | hip and hop cassettes in the third intracellular loop, plus an N-terminal short variant | Tissue distribution and local G protein repertoire |
| Principal distribution | Hypothalamus, amygdala, hippocampus, adrenal medulla, pituitary, sympathetic ganglia | Epithelium, smooth muscle, islets, immune cells, suprachiasmatic nucleus |
| Main research focus | Stress biology, fear conditioning, migraine, reported PTSD risk association in women | Inflammation, bronchodilation, secretion, circadian timing |
PAC1 binds PACAP-38 and PACAP-27 with roughly 100 to 1000 fold higher affinity than VIP, making it functionally a PACAP-selective receptor that enters VIP experiments only as a high-concentration confound.
Termination runs on two clocks at once, and the extracellular one is far faster. Native VIP is cleared in roughly one to two minutes by neutral endopeptidase, dipeptidyl peptidase IV, mast cell tryptase and chymase, and nonspecific proteolysis, with rapid hepatic and pulmonary extraction on top of that. That single number is why the natural peptide behaves as a local, pulsatile paracrine and neurotransmitter signal rather than a hormone holding a steady systemic tone.
Native VIP is cleared with a plasma half-life of roughly one to two minutes, so peptide programs have targeted the degradation clock through D-amino acid substitutions, C-terminal amidation and cyclization, lipidation, PEGylation, albumin binding, and depot or inhaled delivery rather than the receptor clock.
Dysregulation cuts in both directions, and the two failure modes look nothing alike. Excess signaling has one clean clinical example, while deficiency shows up as pulmonary hypertension, bronchoconstriction, gut dysmotility, and a permissive immune state. Therapeutic agonism carries a third and separate risk, since the receptors are distributed widely enough that systemic dosing produces cardiovascular effects well below the doses some target tissues need.
Continuous VIP excess in VIPoma produces secretory diarrhea often exceeding three litres per day with hypokalemia and achlorhydria, while loss of VPAC2 signaling fragments circadian output into arrhythmic activity, blunted melatonin and cortisol rhythms, and disturbed sleep architecture.
Educational use only. This article describes what the published scientific and clinical literature reports about Vasoactive Intestinal Peptide (VIP). It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
Talk to a licensed prescriber. Whether a treatment described here is appropriate for you depends on your medical history, your current medications, and the monitoring you may need. A licensed healthcare provider can evaluate your situation.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
